Drugs /

sasanlimab

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.

Clinical Trials

View Clinical Trials for sasanlimab

Sasanlimab has been investigated in 8 clinical trials, of which 7 are open and 1 is closed. Of the trials investigating sasanlimab, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 3 (1 open).

PD-L1 High Expression (TPS >= 1%), PD-L1 Low Expression (TPS >= 1%), and ALK Fusion are the most frequent biomarker inclusion criteria for sasanlimab clinical trials.

Clear cell renal cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma are the most common diseases being investigated in sasanlimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sasanlimab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sasanlimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sasanlimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-pd-1 checkpoint inhibitor pf-06801591, pf-06801591, who 11161
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C124058

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.